Ovarian Cancer Treatment Landscape and Beyond

Dr. Kwon is a Gynecologic Oncologist, Vice Head and Professor in the Department of Obstetrics and Gynecology at UBC. She also serves as Chair of the Priority and Evaluations Committee at BC Cancer, and Chair of the National BRCA Collaborative for the Society of Gynecologic Oncology of Canada. Her expertise is in hereditary cancer syndromes and conducting cost-effectiveness analyses of testing criteria and risk-reducing interventions. Her training background includes a Masters degree in Public Health from Harvard, and an appointment at the University of Texas M.D. Anderson Cancer Center in Houston. She currently holds a Health Professional Investigator Award from the Michael Smith Foundation for Health Research.

Dr. Anna Tinker is a Medical Oncologist at the British Columbia Cancer, Vancouver Centre and a Clinical Associate Professor in the Department of Medicine at the University of British Columbia. Her clinical expertise is in the treatment of women with gynecologic cancers. She is presently the Chair of the Provincial Gyne Oncology Tumour Group. She is an active member of the Canadian Cancer Trials Group, participating as study chair, Co-Lead of the Ovarian Cancer Working Group Committee and she serves on the Gynecologic Cancers Steering Committee – Ovarian Task Force for the National Cancer Institute (US). She is presently co-leading the GOC Immunotherapy CoP with Dr. Liat Hogen.

Dr. Robert Coleman is Chief Scientific Officer for US Oncology Research, McKesson Corporation. Dr. Coleman received his doctor of medicine degree from Creighton University in Omaha, Nebraska and completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois. He then completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. Prior to joining the M.D. Anderson faculty, he served as Vice Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center in Dallas.

Dr. Coleman’s research interests include drug discovery and novel therapeutics for ovarian, uterine, and cervical cancer, clinical trial development and statistical design. He serves as the institution’s Gynecologic Oncology Group (GOG) principal investigator (PI), serves on the NRG’s (formerly the Gynecologic Oncology Group) Ovarian and Developmental Therapeutics Committees, and is PI or co-PI for several GOG prospective clinical trials. He currently is a co-project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, the Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers. He also serves as Physician Champion and PI for a new human therapeutic leveraging nanoparticle delivery of gene silencing non-coding RNA (siRNA). He has developed a mentoring program for junior investigator clinical trialists.

Dr. Coleman has authored or co-authored over 400 scientific publications, including over 250 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers, Prognostic and Predictive Factors in Gynecological Cancers, and Atlas of Gynecologic Oncology. In 2012, Dr Coleman was elected to the position of Secretary-Treasurer for the International Gynecologic Cancer Society and was Program Chair for their 2012 biannual meeting. In 2015, he was elected President of the Society of Gynecologic Oncology. He currently serves on the Gynecologic Oncology Group’s Board of Directors.